<PAGE> 1
<TABLE>
<S> <C>
---------------------------
UNITED STATES OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION ---------------------------
WASHINGTON, D.C. 20549 OMB Number: 3235-0191
Expires: November 30, 1996
Estimated average burden
hours per response.....0.20
---------------------------
</TABLE>
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13a-17 OR 15d-17 THEREUNDER
Genome Therapeutics Corp.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
100 Beaver Street, Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (617) 893-5007
---------------------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of
shares outstanding:
1. Title of security Common stock: $.10 par value
----------------------------------------------------------
2. Number of shares outstanding before the change 13,803,964
-----------------------------
3. Number of shares outstanding after the change 16,803,964
------------------------------
4. Effective date of change February 22, 1996
---------------------------------------------------
5. Method of changes:
Specify method (such as merger, acquisitions, exchange, distribution, stock
split, reverse split, reverse split, acquisition of stock for treasury,
etc.) Public offering
----------------------------------------------------------------------
Give brief description of transaction Public offering of 3,000,000 shares
of common stock, $.10 par value. -------------------------------------
----------------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
-------------------------------------------------------
2. Name after change
----------------------------------------------------------
3. Effective date of charter amendment changing name
--------------------------
4. Date of shareholder approval of change, if required
-------------------------
Date February 22, 1996
--------------------------- /s/ Fenel M. Eloi
(Officer's signature and title)
VP, CFO, Treasurer
